Stock Traders Purchase High Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the recipient of unusually large options trading on Monday. Traders purchased 11,259 call options on the stock. This is an increase of approximately 2,053% compared to the typical daily volume of 523 call options.

Hedge Funds Weigh In On Sangamo Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Miracle Mile Advisors LLC bought a new stake in shares of Sangamo Therapeutics in the third quarter valued at about $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Sangamo Therapeutics in the 3rd quarter valued at approximately $26,000. Mackenzie Financial Corp raised its position in Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 31,003 shares during the last quarter. SG Americas Securities LLC lifted its stake in Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 63,612 shares in the last quarter. Finally, Golden State Equity Partners boosted its position in Sangamo Therapeutics by 22.5% during the 3rd quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 30,500 shares during the last quarter. Institutional investors own 56.93% of the company’s stock.

Wall Street Analysts Forecast Growth

SGMO has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price target (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research note on Tuesday, February 13th. They issued a “sell” rating on the stock. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.93.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.51 on Tuesday. Sangamo Therapeutics has a 52 week low of $0.29 and a 52 week high of $1.78. The company’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $0.59. The company has a market capitalization of $91.26 million, a P/E ratio of -0.35 and a beta of 1.39.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. Analysts forecast that Sangamo Therapeutics will post -0.54 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.